Back

Risk factors of 30-day mortality following cardiac surgery in adults with congenital heart disease: analysis from the Japanese registry

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Surgery in congenital heart disease: room for improvement Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Takumi Osawa

Tsukuba University Hospital, Tsukuba (Japan)

7 More presentations in this session

Presentation thumbnail
Is it useful to washing stored red blood cells in cardiopulmonary bypass priming fluid for neonatal cardiac surgery
Doctor H. Wang (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Soluble transferrin receptor is associated with red blood cell transfusion in infant cardiac surgery
Doctor J. Liu (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Stem cell seeding of decellularised porcine right ventricular outflow tracts to advance repair of congenital heart defects
Miss A. Harris (Bristol, GB)
Abstract Slides Video
Presentation thumbnail
No association between the novel international classification of bicuspid aortic valve anatomy and performed surgery of the valve or aorta
Doctor S. Wulffeld (Roskilde, DK)
Abstract Slides Video
Presentation thumbnail
Late pseudo-aneurysms after coarctation repair with extra-anatomic ascending-descending aortic bypass surgery
Doctor F. Bonassin Tempesta (Zurich, CH)
Abstract Slides Video

Access the full session

Session thumbnail
Surgery in congenital heart disease: room for improvement

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Heart failure burden among adults with congenital heart disease
thumbnail
Congress Presentation
Mortality and survival rate in a scottish cohort of adults with congenital heart disease.
thumbnail
Congress Presentation
Comparison of long-term prognosis between coronary artery disease and peripheral artery disease in haemodialysis and non-dialysis patients

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources